‘Another benefit’: The pill shown to reduce ovarian cancer risk Australian research finds the oral contraceptive pill can reduce risk of the cancer by 26% among women who have used it at any age.
Another potential long COVID treatment ruled out A COVID-19 antiviral has been shown to be ineffective at treating the condition, as doctors continue to be left with few options.
OCP pharmacy pilot announced for WA While the RACGP does not support pharmacy prescribing, its place on the working group is an opportunity to minimise risk.
Study questions Paxlovid’s COVID-19 ‘usefulness’ Researchers say the antiviral does little to reduce symptom duration for some vaccinated patients, but still recommended its use for the vulnerable.
Tighten Paxlovid eligibility: PBAC advice The committee that looks at PBS listings has recommended the first-line COVID-19 treatment be limited to the highest risk patients aged 50–69 years.
GPs’ role in early detection of oral cancer now easier A new CPD activity aims to upskill GPs in prevention counselling, early identification and referral pathways for the cancer.
Molnupiravir linked to COVID mutations Researchers found the widely used antiviral could be driving new SARS-CoV-2 variants, but there is no evidence these pose any additional threat.
Anti-inflammatory could boost emergency contraceptive: Study Researchers have called for further work into what they have called the ‘really exciting’ findings of a trial undertaken in Hong Kong.
GPs able to initiate FP 50 prescriptions again The revised listing follows a concerted advocacy campaign and was confirmed on the same day as a number of other PBS changes.
GP support for changes that would help end ‘cycle of poverty’ An RACGP submission has recommended several initiatives aimed at improving access to dental care.